Archives: “Drug Repurposing”

Defining Endotypes in Hidradenitis Suppurativa to Improve Treatment

Using spatial transcriptomics to map distinct HS disease endotypes and identify targeted therapeutic strategies for this underserved inflammatory skin disease.

A Novel Skin-Based Approach to Treat Lupus Nephritis

Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.

In Vivo Target Identification and Machine Learning Validation of Autoimmune T Cell Tissue Residence

Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.

High-Throughput Center for AutoImmune Therapeutic Discovery (HIT-AI)

Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study

Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody

Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

Expert perspective: diagnosis and treatment of Castleman disease

A lupus-derived autoantibody that binds to intracellular RNA activates cGAS-mediated tumor immunity and can deliver RNA into cells

A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients